Quick Take
Legend Biotech Corp. (LEGN) has filed to raise $100 million in an IPO of its ADSs representing ordinary shares, according to an F-1 registration statement.
Legend Biotech is spinning out from parent firm GenScript Biotech to pursue treatments in CAR T cell therapies for multiple myeloma.
LEGN has produced promising Phase 2 trial results for its lead candidate.
I’ll provide a final opinion when we learn more IPO details from management.
Company & Technology
Somerset, New Jersey-based Legend was founded within GenScript Biotech to advance a pipeline of drug treatment